In plain language
BPC-157 is a lab-made peptide based on a protein found in stomach fluid. In animal studies it appears to speed the healing of tendons, muscle, and the gut lining. Human evidence is still very limited, so what we know comes mostly from rodents, not people.
What it is explored for
BPC-157 is one of the most talked-about recovery peptides, and it is easy to see why. In research it appears to support several repair pathways at once, from new blood-vessel growth to collagen and the gut lining. Here is where interest and reported use are highest.
- Tendon, ligament, and muscle recovery
- Gut and digestive lining health
- Wound and soft-tissue healing
- Joint comfort and mobility
- Calming inflammation
- Healthy blood flow and circulation
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
BPC-157 is a stable fragment derived from a protein in human gastric juice. In preclinical models it is reported to interact with several healing pathways at once, rather than a single receptor.
- Angiogenesis. Promotes new blood-vessel formation (in part via VEGFR2 signaling) at injury sites in animals.
- Growth-factor & collagen activity. Associated with increased fibroblast activity and collagen organization in healing tendon models.
- Nitric-oxide pathway. Interacts with the NO system, which may underlie reported vascular and cytoprotective effects.
Each mechanism above is observed primarily in animal and cell studies. The pathways in humans are not yet established.
Research applications, by goal
What BPC-157 has actually been studied for, with the strongest level of evidence behind each.
Evidence summary
The evidence base for BPC-157 is broad in animals but thin in humans. Dozens of rodent studies report wound, tendon, and gut healing effects, and they are reasonably consistent. However, there are no published, well-controlled human trials, so it is not possible to say whether these effects translate to people.
Research-reported dosing
This is not a recommendation. The figures below describe dosing used in research studies. Human dosing is not necessarily established. Nothing here is medical or prescribing advice.
| Context | Reported in research | Source |
|---|---|---|
| Rodent tendon-healing models | ~10 µg/kg body weight | Animal study |
| Rodent GI-injury models | ~10 µg-10 ng/kg range | Preclinical reviews |
| Human protocols | Not established | No controlled trials |
Display of this field is controlled by a single site-wide editorial setting and can be turned off across all profiles at once.
Reported safety & side effects
In animal studies, BPC-157 has generally been reported as well-tolerated, with a wide margin between effective and toxic doses. This does not establish human safety. Long-term effects, drug interactions, and risks in people are unknown.
Stacking notes
Full stacking guideTwo repair peptides with different reported mechanisms (BPC-157 favors angiogenesis and gut lining, TB-500 favors cell migration). They are commonly paired in recovery research, though human evidence for either remains limited.
TB-500General educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Key studies
All studies- Animal Journal of Orthopaedic Research · 2010Effect of BPC-157 on tendon-to-bone healing in a rat model
In this rat model, animals given BPC-157 showed faster recovery of tendon-to-bone attachment strength than saline-treated controls. Because the study was conducted only in rodents, the results do not establish whether a similar effect occurs in humans.
- Review (animal) Current Pharmaceutical Design · 2018BPC-157 and gastrointestinal cytoprotection along the gut-brain axis
This review summarizes preclinical reports in which BPC-157 was associated with protection of the gastrointestinal lining and signaling along the gut-brain axis in animal models. The authors note that the underlying studies are largely in rodents and that human evidence is lacking.
- Review (animal) Biomedicines · 2022Reported neuroprotective effects of BPC-157 in animal models of CNS injury
The review collects animal studies in which BPC-157 was associated with reduced injury markers across several central-nervous-system models. The authors describe the findings as early-stage and emphasize that no controlled human studies support these observations.
Frequently asked
Is BPC-157 FDA-approved?
No. BPC-157 is not approved by the FDA for any use. It is sold as a research chemical and is not an approved medicine.
Is there human evidence?
Very little. The large majority of published studies are in rats and in cell models. Well-controlled human trials have not been published, so effects and safety in people are not established.
How is it usually studied?
Most animal studies use injection (often expressed per kilogram of body weight). Human dosing protocols are not established, which is why we report only what research used, not a recommendation.